Drug Patent Expirations for May 7 2013

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for May 7 2013

Tradename	Applicant	Generic Name	Patent Expiration
GEMZAR	Lilly	gemcitabine hydrochloride	May 7, 2013
HUMALOG	Lilly	insulin lispro recombinant	May 7, 2013
HUMALOG KWIKPEN	Lilly	insulin lispro recombinant	May 7, 2013
HUMALOG MIX 50/50	Lilly	insulin lispro protamine recombinant; insulin lispro recombinant	May 7, 2013
HUMALOG MIX 50/50 KWIKPEN	Lilly	insulin lispro protamine recombinant; insulin lispro recombinant	May 7, 2013
HUMALOG MIX 75/25	Lilly	insulin lispro protamine recombinant; insulin lispro recombinant	May 7, 2013
HUMALOG MIX 75/25 KWIKPEN	Lilly	insulin lispro protamine recombinant; insulin lispro recombinant	May 7, 2013
HUMALOG PEN	Lilly	insulin lispro recombinant	May 7, 2013
PREVACID	Takeda Pharms Usa	lansoprazole	May 7, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

DrugPatentWatch Infographics

Which pharmaceutical companies recieved the most drug approvals last
year

Which Companies had the Most Drug Approvals Last Year?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:

Patent litigation
Clinical trial information
International patent families
International patent priority and PCT information
Patent maintenance
Full-text patent downloads
Paragraph IV challenges
Tentative approvals
Drug Master Files
Dynamic search capabilities with data export
More…

See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Drug Patent Expirations for May 14 2013

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for May 14 2013

Tradename	Applicant	Generic Name	Patent Expiration
DEPOCYT	Pacira Pharms Inc	cytarabine	May 14, 2013
ZOMIG	Astrazeneca	zolmitriptan	May 14, 2013
ZOMIG	Ipr	zolmitriptan	May 14, 2013
ZOMIG-ZMT	Astrazeneca	zolmitriptan	May 14, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

DrugPatentWatch Infographics

Which Companies had the Most Drug Approvals Last Year?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:

Patent litigation
Clinical trial information
International patent families
International patent priority and PCT information
Patent maintenance
Full-text patent downloads
Paragraph IV challenges
Tentative approvals
Drug Master Files
Dynamic search capabilities with data export
More…

See the Database Preview and Plan Comparison. Contact Us with any questions.

Drug Patent Expirations for May 13 2013

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for May 13 2013

Tradename	Applicant	Generic Name	Patent Expiration
ZAVESCA	Actelion Pharms Ltd	miglustat	May 13, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

DrugPatentWatch Infographics

Which Companies had the Most Drug Approvals Last Year?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:

Patent litigation
Clinical trial information
International patent families
International patent priority and PCT information
Patent maintenance
Full-text patent downloads
Paragraph IV challenges
Tentative approvals
Drug Master Files
Dynamic search capabilities with data export
More…

See the Database Preview and Plan Comparison. Contact Us with any questions.

Drug Patent Expirations for May 18 2013

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for May 18 2013

Tradename	Applicant	Generic Name	Patent Expiration
OSMOPREP	Salix Pharms	sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate	May 18, 2013
VISICOL	Salix Pharms	sodium phosphate, dibasic anhydrous; sodium phosphate, monobasic, monohydrate	May 18, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

DrugPatentWatch Infographics

Which Companies had the Most Drug Approvals Last Year?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:

Patent litigation
Clinical trial information
International patent families
International patent priority and PCT information
Patent maintenance
Full-text patent downloads
Paragraph IV challenges
Tentative approvals
Drug Master Files
Dynamic search capabilities with data export
More…

See the Database Preview and Plan Comparison. Contact Us with any questions.

Singapore’s biomedical science sector development strategy: Is it sustainable?

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Singapore's biomedical science sector development strategy: Is it sustainable?

Go to paper

ABSTRACT: This paper outlines the strategic efforts undertaken by Singapore to establish its national capability in the biomedical science sector, reviews the commercial base as a result of these efforts and compares Singapore's approach with the UK and US development models, discusses the challenges that Singapore faces and raises some questions on the long-term sustainability of the sector...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as: